
Keywords: ETV; Entecavir; LAMr; lamivudine resistance mutations; VBT; viral breakthrough; HBV; Hepatitis B virus; HCC; hepatocellular carcinoma; IFN-α-2b; interferon α-2b; PegIFN-α-2a; pegylated interferon; NAs; α-2a nucleos(t)ide analogues; LAM; lamivudine; AD